These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550 [TBL] [Abstract][Full Text] [Related]
12. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Vlasschaert C; Sidhu B; Silver SA Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064 [TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
14. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032 [TBL] [Abstract][Full Text] [Related]
15. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC; Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417 [TBL] [Abstract][Full Text] [Related]
16. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232 [TBL] [Abstract][Full Text] [Related]
17. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations. Kotit S Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098 [TBL] [Abstract][Full Text] [Related]
18. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial. Sharma A; Ferreira JP; Zannad F; Pocock SJ; Filippatos G; Pfarr E; Petrini M; Kraus BJ; Wanner C; Packer M; Butler J; Anker SD Eur J Heart Fail; 2023 Aug; 25(8):1337-1348. PubMed ID: 37062851 [TBL] [Abstract][Full Text] [Related]
19. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Fernández-Fernandez B; Sarafidis P; Soler MJ; Ortiz A Clin Kidney J; 2023 Aug; 16(8):1187-1198. PubMed ID: 37529652 [TBL] [Abstract][Full Text] [Related]